BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 10091100)

  • 1. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide in control of multiple liver metastases from gastrinoma.
    Saijo F; Naito H; Funayama Y; Fukushima K; Shibata C; Hashimoto A; Kitayama T; Nagao M; Matsuno S; Sasaki I
    J Gastroenterol; 2003; 38(9):905-8. PubMed ID: 14564638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients.
    Nikou GC; Toubanakis C; Nikolaou P; Giannatou E; Marinou K; Safioleas M; Karamanolis D
    Hepatogastroenterology; 2005; 52(66):1668-76. PubMed ID: 16334754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
    Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
    Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
    Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
    Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours.
    Zamora V; Cabanne A; Salanova R; Bestani C; Domenichini E; Marmissolle F; Giacomi N; O'Connor J; Méndez G; Roca E;
    Dig Liver Dis; 2010 Mar; 42(3):220-5. PubMed ID: 19819769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.
    Granberg D; Jacobsson H; Oberg K; Gustavsson J; Lehtihet M
    Digestion; 2008; 77(2):92-5. PubMed ID: 18376130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.